That is absolutely consistent with an allelic series of promiscuous cannabinoid synthase enzymes. Some tuned more to a CBD endpoint, others to THC. Adjustable as environment dictates.
I’ve got a CBD strain that averages about 16% CBD in trimmed flower. CBD:THC ratio varies between 15:1 and 100:1.
Some of that variance is undoubtedly machine calibration, with the THC being near the limit of quantification. But I assume much of it is varying growth conditions.
Given that we don’t seem to have many independent sources for the CBD allele(s?) we’re using, it would be reasonable to surmise that much of the variation in CBD:THC ratios has to do with other genetic modifiers. eg genes that affect cellular pH.
I don’t believe this is the patent you were referring to, but it does claim pH as a modifier of cannabinoid ratio.
And then there is an excerpt from DJ Potters PhD thesis suggesting that temperature can affect the ratio. I suspect that it’s more about lowering the off target production of THC by the CBD allele than competition between two synthases
“…where these clones were grown in a growth room in identical conditions apart from contrasting growth temperature of 15ºC and 25ºC, the cooler temperature significantly increased the proportion of CBD within the cannabinoid profile. A possible explanation is that in cooler conditions the CBD synthase within these plants is able to compete more favorably than THC synthase for the common precursor CBGA. No previous reports could be found describing this temperature effect.”